Azenta has completed the sale of its B Medical Systems business to Thelema S.à r.l. for $63 million, a deal announced in December 2025 and finalized on July 1, 2026. This divestment aligns with Azenta’s strategy to refine its focus on core life sciences operations, enhancing financial flexibility and enabling further investment in sample management solutions and multiomics services. The transaction involved a short-term secured vendor loan of $35 million from an Azenta subsidiary to finance part of the purchase. CEO John Marotta emphasized the move as a step toward sustainable growth and shareholder value.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://pulse2.com/azenta-completes-sale-of-b-medical-systems-to-streamline-its-life-sciences-portfolio/
